GlassScriptPhysician profile
James L Grobe
NPI 1538115019
$1,857.25
in general payments reported to CMS, 2019-2025
13 companies · $367 in 2025
The $367 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $411 · 2021: $295 · 2022: $97.09 · 2023: $63.32 · 2024: $291 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $674.56 | 2020-2025 | |
| Janssen Biotech, INC. | $347.54 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $306.91 | 2019-2025 | Entyvio |
| Pfizer INC. | $122.35 | 2019 | |
| Ironwood Pharmaceuticals, INC | $95.67 | 2020 | |
| Covidien LP | $87.42 | 2019 | |
| Allergan, INC. | $61.06 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $42.87 | 2022 | |
| Celltrion USA INC. | $34.18 | 2024 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $25.07 | 2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $23.60 | 2019 | |
| Ardelyx, INC. | $19.55 | 2023 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.47 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Grobe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.